Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: A trial of the ECOG-ACRIN cancer research group (E2810).

Category Primary study
JournalJOURNAL OF CLINICAL ONCOLOGY
Year 2019
This article has no abstract
Epistemonikos ID: 3ffd148406738b3ce9ec8512c29ce7984c7c6404
First added on: Feb 11, 2025